Distinguished in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)

George J. Kahaly

Mainz, RP, DE 
Distinguished in Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)
Mainz, RP, DE 
OverviewLocationsClinical Research

Overview

George Kahaly practices in Mainz, Germany. Mr. Kahaly is rated as a Distinguished expert by MediFind in the treatment of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED). His top areas of expertise are Graves Disease, Hyperthyroidism, Thyroid Eye Disease, Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED), and Thyroidectomy.

His clinical research consists of co-authoring 186 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles in the study of Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED).

Gender
Male

Locations

Mainz, RP, Germany
Other Locations
Hirschhorn, RP, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: July 11, 2024
Intervention Type: Other, Biological
Study Phase: Phase 3
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

187 Total Publications

Bibliometrics in thyroid eye disease.
Bibliometrics in thyroid eye disease.
Journal: Journal of endocrinological investigation
Published: July 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kahaly's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile